— Know what they know.
Not Investment Advice
Also trades as: LLY.DE (XETRA) · $vol 2M · LLY.SW (SIX) · $vol 0M

LLY NYSE

Eli Lilly and Company
1W: +3.9% 1M: +1.0% 3M: +40.6% YTD: +13.2% 1Y: +50.8% 3Y: +169.0% 5Y: +442.6%
$1,222.61
+25.08 (+2.09%)
After Hours: $1223.32 (+0.71, +0.06%)
Weekly Expected Move ±5.3%
$1069 $1132 $1196 $1260 $1324
NYSE · Healthcare · Drug Manufacturers - General · Alpha Radar Buy · Power 71 · $1.15T mcap · 847M float · 0.373% daily turnover · Short 45% of daily vol
Smart Money Score
Moderate 50
Insider
Congress6 trades
ETF Holdings
Key Statistics
Market Cap$1.15T
52W Range623.78-1249.45
Volume1,794,303
Avg Volume3,158,375
Beta0.51
Dividend$6.46
Analyst Ratings
33 Buy 9 Hold 3 Sell
Consensus Buy
Company Info
CEODavid A. Ricks
Employees50,000
SectorHealthcare
IndustryDrug Manufacturers - General
IPO Date1972-06-01
Websitelilly.com
Lilly Corporate Center
Indianapolis, IN 46285
US
317 276 2000
About Eli Lilly and Company

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

Recent Insider Trades

NameTypeSharesPriceDate
Sulzberger Gabrielle A-Award 4 $1,146.90 2026-07-20
LUCIANO JUAN R A-Award 14 $1,146.90 2026-07-20
Fyrwald J Erik A-Award 9 $1,146.90 2026-07-20
Alvarez Ralph A-Award 11 $1,146.90 2026-07-20
Fyrwald J Erik A-Award 9 $1,129.35 2026-06-15

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms